loading page

Efficacy and prognosis of CT-guided of 125I radioactive seeds implantation brachytherapy as salvage treatment for recurrent nasopharyngeal carcinoma after external beam radiotherapy--A long-term experience at a single institution
  • +8
  • xuemin li,
  • Yuliang Jiang,
  • Zhe Ji,
  • Ran Peng,
  • Fuxin Guo,
  • Yi Chen,
  • Shuhua Wei,
  • Haitao Haitao Sun,
  • Jinghong Fan,
  • Weiyan Li,
  • Junjie Wang
xuemin li
Peking University Third Hospital
Author Profile
Yuliang Jiang
Peking University Third Hospital
Author Profile
Zhe Ji
Peking University Third Hospital
Author Profile
Ran Peng
Peking University Third Hospital
Author Profile
Fuxin Guo
Peking University Third Hospital
Author Profile
Yi Chen
Peking University Third Hospital
Author Profile
Shuhua Wei
Peking University Third Hospital
Author Profile
Haitao Haitao Sun
Peking University Third Hospital
Author Profile
Jinghong Fan
Peking University Third Hospital
Author Profile
Weiyan Li
Peking University Third Hospital
Author Profile
Junjie Wang
Peking University Third Hospital
Author Profile

Abstract

Background: To assess the efficacy and prognosis of computed tomography (CT)-guided 125I radioactive seeds implantation brachytherapy (RSI-BT) for recurrent nasopharyngeal carcinoma (NPC) after external beam radiotherapy (EBRT). Methods: Thirty-one patients with recurrent NPC (forty-one lesions) after EBRT from February 2003 to January 2019 were enrolled in this retrospective study. The work-follow of CT-guidance RSI-BT was: indication selection, patient set-up and immobilization on CT couch, CT-simulation, preoperative planning, prescription doses (PD) definition of 110-160Gy, seed implantation, postoperative dosimetric evaluation and postoperative follow-up. Median radioactivity of RSI was 0.43 (range 0.22-0.79, average 0.61) mCi. Median actuarial number of 125I seeds was 24 (range 3-83, average 37). Median value of post-operative D90 was 118.5 (range 62.4-246, average 136.2) Gy. Local control (LC) and overall survival (OS) were investigated for their relationship with the prognosis. The adverse events were evaluated by the Radiation Therapy Oncology Group (RTOG) classification criteria. Results: Median follow-up was 41.9 (range 2.1-60.2, average 44.1) months. Median LC was 35.8 (range 2.1-60.2, average 34.9) months. LC at 1-, 3- and 5-year was 71.3%, 41.9% and 27.9%, respectively. Median OS was 22.6 (range 2.1~60.2, average 27.1) months. OS at 1-, 3- and 5-years was 57.7%, 23.8% and 11.9%, respectively. Univariate analysis suggested that sex (P=0.037) and frequency of previous EBRT (P=0.001) were prognostic factors influencing LC. Moreover, univariate analysis also suggested that frequency of previous EBRT (P=0.012) was prognostic factors influencing OS. Prevalence of side effects (≥grade 3) was 6.5%. Conclusion: 125I RSI-BT was a safe and feasible salvage treatment for recurrent NPC after EBRT. Key words: recurrent nasopharyngeal carcinoma; External beam radiotherapy; 125I seed implantation brachytherapy; overall survival; local control; side effects.

Peer review status:IN REVISION

16 Aug 2020Submitted to Clinical Otolaryngology
30 Nov 2020Assigned to Editor
30 Nov 2020Submission Checks Completed
06 Dec 2020Editorial Decision: Revise Minor
06 Dec 20201st Revision Received